An underground market for unlicensed slimming drugs is being driven by social media fitness personalities and sellers on messaging platforms, based on recent findings.
Investigational Drug Acquiring Traction Via Social Media
The experimental drug, which is still in research studies, is being promoted by social media influencers for its alleged weight-reducing properties. Followers are encouraged to message these accounts privately for supplier links, while also obtaining promotional offers.
Active Trade on Messaging Platforms
Additionally, a flourishing market exists on messaging services, where communities with thousands of members share comparison images, injection guides and assertions of next-day UK delivery. Vendors promote the drug there before redirecting customers to other platforms for transactions.
Learning About Retatrutide
Retatrutide is an investigational injectable created by US drugmaker Eli Lilly. The treatment affects three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Early trials suggest it could assist patients lose up to a quarter of their body weight. Nicknamed the “triple G”, the drug is being promoted online as the next Ozempic.
Healthcare Professionals Voice Concerns
Nevertheless, physicians and chemists have cautions that the sale of what remains an unapproved medication in the United Kingdom is worrisome and could result in individuals administering products of unknown origin.
Several professionals stated the demand for retatrutide could be connected to the increasing cost of approved slimming products such as Mounjaro.
Legal Status and Enforcement
Selling retatrutide on social media or Telegram is illegal in the United Kingdom, as it is an unlicensed medication that must not be promoted or supplied for human use under the Human Medicines Regulations 2012.
Some content creators attempt to sidestep the regulations by referring to the substance as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a controlled drug, but advertising and supply can still breach medicines, marketing, and customer laws, risking fines, legal action or imprisonment.
Service Reaction and Content Elimination
Based on the social media company, the platform has removed violative content and banned related keywords and search suggestions. The organization stated it was committed to maintaining the platform secure and allocating resources in strengthening enforcement strategies.
Online Marketplace Operations
Research also found groups with up to 9,000 participants marketing the experimental drug using the platform's integrated search feature, which functions like a public directory. Entering “retatrutide” immediately displays groups with thousands of members, populated with images of slimming results, positive reviews and step-by-step guides for mixing or injecting at home.
Within minutes of joining one group, a seller posted WhatsApp details, where the majority of purchases take place. The seller provided an guidebook and guaranteed delivery within two days. When asked whether the product was authentic, one seller said: “You can’t be sure.” Another shared a photo of a alleged laboratory certificate. None inquired about weight, health issues or past usage.
Item Details and Costs
Within these groups, messages display black plastic packages with Royal Mail labels, claiming to include new batches. One message stated: “It took eight of us to load them this morning.”
Customers can select between dry substance containers, mixed at home with sterile water, or pre-filled pens typically priced at 160 pounds for 20 milligrams. When asked how much time a injector should be used, vendors give conflicting answers ranging from a several days to “depends on your body”.
Service Moderation and Security Actions
A representative for the messaging service stated it actively moderated harmful material on its platform including content that promoted the “misuse of controlled medications”. The company noted that it eliminated “millions of pieces of harmful content each day”.
Medical Professional Warnings
“People are administering substances they cannot confirm. Even if the science behind retatrutide is sound, these digital versions may not contain what they claim,” stated Jason Murphy, the director of pharmaceutical services at a pharmacy service.
Dr Crystal Wyllie of Asda Online Doctor linked the surge in demand to recent cost increases for approved slimming medications such as Mounjaro. “With costs rising, individuals are turning to social media. But counterfeit treatments are highly risky. You can’t be certain what’s inside or whether the environment they were produced in was clean,” she explained.
Her staff has already seen individuals injured by personal administration from unconfirmed suppliers. “We understand the frustration, but buying from Telegram or communication platforms is gambling with your health,” said the doctor. “These materials could be impure or improperly measured.”
Manufacturer Position
A spokesperson from Eli Lilly said retatrutide was in phase 3 research studies and had not been evaluated or approved by any regulatory agency anywhere in the world. “Consequently at this point no one can sell [it] for human use,” they explained, adding that any product “misleadingly claiming itself as a Lilly experimental product not yet approved … may subject patients to possibly significant health risks”.
